A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma
Nagarajan Pattabiraman, Cosimo Lobello, David Rushmore, Shengchun Wang, Luca Mologni, Hossein Borgh, Kavindra Nath, Wujuan Zhang, Aaron R. Goldman, Reza Nejati, Mariusz A. Wasik, Johnvesly Basappa
This paper identifies VCB1, a novel ACLY inhibitor, which overcomes TKI resistance in lymphoma by disrupting lipid and nucleotide metabolism, ISR, and redox homeostasis.
bioRxiv · Oct 4, 2026 · PreprintCancer Biology